Emeryville, United States
Totus Medicines, founded in 2020, is an emerging leader in the Biopharma and Biotechnology sectors, headquartered in the United States. The company is committed to its bold vision of "Making every disease treatable by making the total human genome druggable." By leveraging groundbreaking chemical biology technologies, Totus Medicines aims to develop transformative covalent therapeutics targeting currently untreatable diseases.
The company recently secured a substantial $66.00M Series B investment from notable investor DCVC as of 01 December 2023. This financial backing serves as strong validation of their innovative approach and positions them well for future growth and development. As Totus Medicines continues to push boundaries in drug discovery, its potential impact on global healthcare positions it as a compelling investment opportunity for venture capitalists focusing on cutting-edge biotechnology ventures.
Enlaza Therapeutics